Ana Teresa Monteiro Amaral

Team icon

Publications

Show less

Information about journal articles, updated at 29-01-2023, from platform CIÊNCIAVITAE.

Endoglin and MMP14 Contribute to Ewing Sarcoma Spreading by Modulation of Cell–Matrix Interactions

Puerto-Camacho, Pilar; Díaz-Martín, Juan; Olmedo-Pelayo, Joaquín; Bolado-Carrancio, Alfonso; Salguero-Aranda, Carmen; Jordán-Pérez, Carmen; Esteban-Medina, Marina; et al, International Journal of Molecular Sciences. 15. 23. 2022. http://dx.doi.org/10.3390/ijms23158657 . 10.3390/ijms23158657 . published International Journal of Molecular Sciences

Endoglin in the Spotlight to Treat Cancer

González Muñoz, Teresa; Amaral, Ana Teresa; Puerto-Camacho, Pilar; Peinado, Héctor; de Álava, Enrique, International Journal of Molecular Sciences. 6. 22. 2021. http://dx.doi.org/10.3390/ijms22063186 . 10.3390/ijms22063186 . International Journal of Molecular Sciences

Selective modulation by PARP-1 of HIF-1a-recruitment to chromatin during hypoxia is required for tumor adaptation to hypoxic conditions

Martí, Juan Manuel; Garcia-Diaz, Angel; Delgado-Bellido, Daniel; O'Valle, Francisco; González-Flores, Ariannys; Carlevaris, Onintza; Rodríguez-Vargas, José Manuel; et al, Redox Biology. 41. 2021. http://dx.doi.org/10.1016/j.redox.2021.101885 . 10.1016/j.redox.2021.101885 . Redox Biology

Hippo pathway effectors YAP1/TAZ induce an EWS–FLI1 -opposing gene signature and associate with disease progression in Ewing sarcoma

The Journal of Pathology. 374 - 386. 4. 250. 2020. http://dx.doi.org/10.1002/path.5379 . 10.1002/path.5379 . The Journal of Pathology

Breakthrough Technologies Reshape the Ewing Sarcoma Molecular Landscape

Cells. 804 - 804. 4. 9. 2020. http://dx.doi.org/10.3390/cells9040804 . 10.3390/cells9040804 . Cells

Preclinical Efficacy of Endoglin-Targeting Antibody–Drug Conjugates for the Treatment of Ewing Sarcoma

Clinical Cancer Research. 2228 - 2240. 7. 25. 2019. http://dx.doi.org/10.1158/1078-0432.ccr-18-0936 . 10.1158/1078-0432.ccr-18-0936 . Clinical Cancer Research

DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma

Nature Medicine. 386 - 395. 3. 23. 2017. http://dx.doi.org/10.1038/nm.4273 . 10.1038/nm.4273 . Nature Medicine

Trabectedin Efficacy in Ewing Sarcoma Is Greatly Increased by Combination with Anti-IGF Signaling Agents

Clinical Cancer Research. 1373 - 1382. 6. 21. 2015. http://dx.doi.org/10.1158/1078-0432.ccr-14-1688 . 10.1158/1078-0432.ccr-14-1688 . Clinical Cancer Research

The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin

Oncotarget. 18875 - 18890. 22. 6. 2015. http://dx.doi.org/10.18632/oncotarget.4303 . 10.18632/oncotarget.4303 . Oncotarget

Bone microenvironment signals in osteosarcoma development

Cellular and Molecular Life Sciences. 3097 - 3113. 16. 72. 2015. http://dx.doi.org/10.1007/s00018-015-1918-y . 10.1007/s00018-015-1918-y . Cellular and Molecular Life Sciences

Ex vivo identification and characterization of a population of CD13high CD105+ CD45- mesenchymal stem cells in human bone marrow

Stem Cell Research & Therapy. 1. 6. 2015. http://dx.doi.org/10.1186/s13287-015-0152-8 . 10.1186/s13287-015-0152-8 . Stem Cell Research & Therapy

Characterization of Human Mesenchymal Stem Cells from Ewing Sarcoma Patients. Pathogenetic Implications

PLoS ONE. e85814 - e85814. 2. 9. 2014. http://dx.doi.org/10.1371/journal.pone.0085814 . 10.1371/journal.pone.0085814 . PLoS ONE

Innovative Therapies in Ewing Sarcoma

Advances in Anatomic Pathology. 44 - 62. 1. 21. 2014. http://dx.doi.org/10.1097/pap.0000000000000003 . 10.1097/pap.0000000000000003 . Advances in Anatomic Pathology

IGF1R Signaling in Ewing Sarcoma Is Shaped by Clathrin-/Caveolin-Dependent Endocytosis

PLoS ONE. e19846 - e19846. 5. 6. 2011. http://dx.doi.org/10.1371/journal.pone.0019846 . 10.1371/journal.pone.0019846 . PLoS ONE

The Clinical Relevance of Molecular Genetics in Soft Tissue Sarcomas

Advances in Anatomic Pathology. 162 - 181. 3. 17. 2010. http://dx.doi.org/10.1097/pap.0b013e3181d98cbf . 10.1097/pap.0b013e3181d98cbf . Advances in Anatomic Pathology

Stable interference of EWS–FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target

British Journal of Cancer. 80 - 90. 1. 101. 2009. http://dx.doi.org/10.1038/sj.bjc.6605104 . 10.1038/sj.bjc.6605104 . British Journal of Cancer

All projects

Show less

Information of exclusive responsibility of the researcher 29-01-2023 , from platform CIÊNCIAVITAE.

2022/01/01 - 2023

Tailored adoptive cellular immunotherapy for Ewing Sarcoma

CI21-00189

Post-doc

Instituto de Biomedicina de Sevilla; Fundación Josep Carreras contra la Leucemia

Funders: Obra Social La Caixa

2021 - 2023

Integrative molecular-testing platform for precision diagnostics and personalized care of sarcoma patients

4becatrienalGEISFMJC

Post-doc

Instituto de Biomedicina de Sevilla; Hospital Universitario Virgen del Rocío

Funders: Fundacion Maripaz Jimenez Casado

2021 - 2022

Intratumoral heterogeneity in t-sarcomas: A silver lining for precision therapeutics

PI20-0003

Post-doc

Instituto de Biomedicina de Sevilla

Funders: Instituto de Salud Carlos III

2020 - 2022

Evaluación de STAT6 como biomarcador de diagnóstico de precisión y diana terapéutica en Tumor Fibroso Solitario

PI-0061-2020

Post-doc

Instituto de Biomedicina de Sevilla; Hospital Universitario Virgen del Rocío

Funders: Junta de Andalucía

2020 - 2023

New insights into the Desmoplastic small round cell tumour: comprehensive molecular characterization to identify therapeutic targets and new biomarkers

400300200313

Principal investigator

Instituto de Biomedicina de Sevilla

Funders: Grupo Espanol Investigacion Sarcomas

2020 - 2023

Study of the prognostic and functional role of mesenchymal stem cell markers Endoglin and ALCAM in the disease progression of Clear cell sarcomas (CCS) and Desmoplastic small Round cell tumors (DSRCT)

P18-RT-735

Principal investigator

Instituto de Biomedicina de Sevilla

Funders: Junta de Andalucía

2019 - 2022/12

CIBERONC-Centro de Investigacio Biomedica en RED: Low prevalence tumours program

G85296226

Post-doc

Centro de Investigación Biomédica en Red de Cáncer

2019 - 2023

Translational assessment of predictive factors of response of Ewing sarcoma to genotoxic therapy

S1900239

Principal investigator

Instituto de Biomedicina de Sevilla; Hospital Universitario Virgen del Rocío; University College London; University of Michigan

Funders: Sarcoma Foundation of America

2018 - 2019

PROYECTO 3D-ID CULTIVOS 3D PERSONALIZADOS PARA SELECCIÓN DE TRATAMIENTO PARA PACIENTES DE CÁNCER EN MEDICINA DE PRECISIÓN

RTC-2017-6573-1

Post-doc

Instituto de Biomedicina de Sevilla; STEMTEK THERAPEUTICS SL; FUNDACIÓN ONKOLOGIKOA FUNDAZIOA; Institut d'Investigació Biomèdica de Bellvitge

2018 - 2020

Nuevas dianas terapéuticas en el sarcoma de Ewing a través del estudio del proceso metastásico

PI1700464

Post-doc

Instituto de Biomedicina de Sevilla

Funders: Instituto de Salud Carlos III

2018 - 2021

Evaluation of the clinical potential of the vesicular crosstalk in response to drugs in the context of Ewing sarcoma. PI-0040-2017

PI-0040-2017

Principal investigator

Instituto de Biomedicina de Sevilla

Funders: Junta de Andalucía

2017 - 2018

PROspective VAlidation of Biomarkers in Ewing Sarcoma for personalized translational medicine

PI2/03102

Post-doc

Hospital Universitario Virgen del Rocío; IRCCS Istituto Ortopedico Rizzoli; St James's University Hospital; Institut Curie; Klinikum rechts der Isar der Technischen Universität München

Funders: European Commission

2014 - 2016

ENDOWING RELEVANCIA DE LA ENDOGLINA EN LA PATOLOGÍA DEL SARCOMA DE EWING: DESARROLLO DE TRATAMIENTOS PERSONALIZADOS INNOVADORES

RTC-2014-2102-1

Post-doc

Instituto de Biomedicina de Sevilla; Oncomatryx

2014 - 2017

Nuevas dianas terapéuticas en el sarcoma de Ewing: estudio del micromedioambiente

PI14/01466

Post-doc

Instituto de Biomedicina de Sevilla

Funders: Instituto de Salud Carlos III

We use cookies to improve your visit to our website.